Novonesis stock (DK0060336014): Kepler Cheuvreux upgrades to Buy

Novonesis, the Danish biotechnology company formed from the merger of Novozymes and Chr. Hansen, received a positive analyst update from Kepler Cheuvreux. On Wednesday, the firm upgraded the stock to Buy from Hold and boosted its price target to 460.00 Danish kroner from a prior level, according to Marketscreener as of recent trading. This move highlights optimism around Novonesis' position in enzymes and microbial solutions for industries like food, pharma, and textiles.

Separately, Novonesis became a bluesign System Partner, reinforcing its commitment to sustainable innovation in textiles and leather, as announced on its investor site, per Marketscreener. The stock trades on Nasdaq Copenhagen under ticker NOVO-B. For US investors, Novonesis offers exposure to global biotech trends via unsponsored ADRs listed as NZM.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Novonesis: core business model

Novonesis develops and supplies biosolutions such as enzymes and microbes that replace traditional chemical processes, enabling more sustainable production worldwide. The company serves key sectors including food and beverages, where its products improve yield and reduce waste; pharmaceuticals for drug manufacturing; and household care for greener detergents. Headquartered in Denmark, Novonesis emerged from the 2024 merger of Novozymes and Chr. Hansen, creating a global leader with over 10,000 employees, according to its investor announcements page.

This integrated model focuses on innovation in biotechnology, with R&D investments driving patented solutions. For US investors, Novonesis provides indirect exposure through its role in supply chains for American giants in food processing and pharma, amid rising demand for eco-friendly alternatives.

Main revenue and product drivers for Novonesis

Revenue stems primarily from biosolutions in Food, Health & Nutrition (largest segment), and Grain & Tech Processing. Enzymes for baking and dairy enhance efficiency, while microbial products support animal nutrition and plant health. In Q1 2025 results published earlier this year, the company reported stable organic growth, per its investor relations site.

Sustainable textiles initiatives, like the recent bluesign partnership, target leather and fabric processing to cut water and energy use. These drivers position Novonesis to benefit from global ESG trends, relevant for US portfolios tracking green biotech.

Industry trends and competitive position

The biotech enzymes market is expanding due to regulatory pushes for sustainability in the EU and US. Novonesis holds a leading share, competing with firms like DSM-Firmenich and DuPont. Its merger synergies have bolstered scale, with a diverse portfolio reducing single-market risks.

Why Novonesis matters for US investors

US investors can access Novonesis via OTC ADRs (NZM), gaining exposure to Europe's biotech innovation without direct Copenhagen trading. The company's products underpin US food giants like Cargill and ADM, linking it to American agricultural and consumer markets amid sustainability mandates.

Conclusion

The Kepler Cheuvreux upgrade to Buy underscores analyst faith in Novonesis' biosolutions growth, complemented by sustainability moves like the bluesign partnership. With a strong foothold in high-demand sectors, the company navigates biotech trends effectively. US investors note its ADR availability and supply chain ties to domestic markets, though currency and regulatory risks persist in global operations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.